<DOC>
	<DOCNO>NCT01521559</DOCNO>
	<brief_summary>This phase III , double-masked , randomize , active-controlled , parallel-group , 52-week study ass efficacy safety Intravitreal Aflibercept Injection ( IAI ; EYLEA® ; BAY86-5321 ) compare laser treatment patient macular edema secondary BRVO .</brief_summary>
	<brief_title>Study Assess Clinical Efficacy Safety Intravitreal Aflibercept Injection ( IAI ; EYLEA® ; BAY86-5321 ) Patients With Branch Retinal Vein Occlusion ( BRVO )</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<criteria>The following inclusion criterion include , limited : 1 . Adults ≥ 18 year age foveal centerinvolved macular edema ( ME ) secondary BRVO diagnose within 12 month screen visit 2 . ETDRS BCVA : letter score 73 24 ( 20/40 20/320 ) study eye screen day 1 3 . Provide sign informed consent The following exclusion criterion include , limited : 1 . Current bilateral manifestation BRVO 2 . Uncontrolled glaucoma define ≥ 25 mmHg optimal medical regimen , previous filtration surgery either study eye fellow eye 3 . Insufficient clear macular hemorrhage would prevent patient receive laser treatment safely day 1 ( patient meet criterion may rescreened macular hemorrhage resolve ) 4 . Uncontrolled diabetes mellitus ( DM ) 5 . Previous use intraocular corticosteroid antiangiogenic drug study eye 6 . Use periocular corticosteroid study eye within 3 month day 1 7 . Use intraocular periocular corticosteroid antiangiogenic drug fellow eye within 3 month day 1 8 . Previous administration systemic antiangiogenic medication 9 . Panretinal scatter photocoagulation , sector laser photocoagulation , macular grid photocoagulation study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>